High-throughput bio-layer interferometry (BLI) has become a game-changer in the development of new drugs, particularly monoclonal antibodies (mAbs) for clinical trials. Utilizing platforms like Octet from Sartorius, companies like Abveris are able to rapidly identify high-affinity mAbs with specific profiles, a process that was previously time-consuming and uncertain. The efficiency of BLI, which enables real-time monitoring of biomolecular interactions, allows researchers to analyze large panels of antibody candidates quickly and accurately, providing a plethora of lead options.
BLI works by analyzing the interference pattern of light reflected from immobilized proteins on biosensor tips, offering precise data on binding specificities, analyte concentrations, and interaction rates. This technology plays a crucial role in epitope binning studies to determine antibody binding sites and in identifying mAbs for various applications, such as biosimilars or biomarker testing. Unlike traditional methods like ELISA, BLI is label-free, providing a faster and more comprehensive view of dynamic interactions without the risk of interference from labels, enabling researchers to make data-driven decisions efficiently.
One of the key strengths of BLI is its ability to provide insights into how antibody candidates behave in vitro, helping researchers predict their impact on targeted biological events, such as in the development of vaccines. By understanding the binding specificity, kinetics, and affinity of antibodies to pathogens like the Hepatitis C virus, researchers can potentially enhance immune responses and develop effective therapeutics. BLI’s scalability and high throughput, capable of processing up to 96 samples in parallel, make it an attractive option for various industry applications, outperforming technologies like surface plasmon resonance (SPR) in terms of efficiency and speed.
The user-friendly nature of BLI, coupled with its fluidic-free design that eliminates sample loading and cleaning steps, not only accelerates the research process but also reduces costs and maintenance efforts. This technology’s versatility extends to analyzing a wide range of biomolecular interactions, including proteins, drugs, viruses, nanoparticles, and DNA, making it a valuable tool for both biopharmaceutical companies and academic research. As the demand for specific, high-affinity molecules continues to rise, the adoption of BLI is expected to grow, driving innovation in drug development and vaccine research.
Tags: clinical trials, monoclonal antibodies, biosensors
Read more on nature.com